TABLE 3B:
Risk Factors Associated With De Novo Inflammatory Bowel After Liver Transplantation
| De Novo IBD | ||
|---|---|---|
| Risk Factors | Univariate Analysis HR (95% CI) | P |
| Demographics | ||
| Age at LT per year | 0.993 (0.961–1.027) | 0.666 |
| Sex (M:F) | 0.68 (0.27–1.74) | 0.411 |
| Smoking (ever:never) | 1.36 (0.24–2.74) | 0.622 |
| Transplant-related variables | ||
| CMV infection (Y:N) | 1.63 (0.37–5.13) | 0.474 |
| CMV mismatch (Y:N) | 1.53 (0.33–5.30) | 0.548 |
| Renal dysfunction at the time of LT (serum Creatinine > 1.3) | 0.57 (0.15–1.71) | 0.329 |
| Type of LT (living donor vs OLT) | 1.28 (0.28–4.34) | 0.714 |
| Immunosuppression | ||
| Tacrolimus-based immunosuppression (vs cyclosporine-based) | 1.23 (0.45–3.94) | 0.698 |
| Mycophenolate mofetil use at LT (Y:N) | 3.32 (1.34–9.43) | <0.001 |
| Azathioprine use at LT (Y:N) | 0.19 (0.13–0.57) | 0.003 |
OLT = orthotopic liver transplant.